This year Memorial Sloan Kettering launched a new Lobular Breast Cancer Program! This new program focusing on improving treatment for patients with lobular breast cancer and increasing important ILC research is one of the first three in the world to launch at a major cancer center.

In this interview with the program’s three co-directors, breast medical oncologist Dr. Sherry Shen, breast surgeon, Dr. Anita Mamtani and LBCA Scientific Advisory Board member and breast pathologist Dr. Fresia Pareja, they lay out the vision for the new program,  discuss some of what is happening and what is in the works. Plans include more collaboration among other new breast cancer programs that will focus on lobular breast cancer and with lobular researchers around the world to accelerate ILC research. In addition, new breast cancer clinical trials that focus specifically on or at least are enriched for lobular breast cancer are being formed and the program directors are committed to working with patient advocates and ensuring that patients with ILC are also made aware of LBCA’s resources and community